Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery

2007 ◽  
Vol 84 (1) ◽  
pp. 161-168 ◽  
Author(s):  
Hemant S. Agarwal ◽  
Jo E. Bennett ◽  
Kevin B. Churchwell ◽  
Karla G. Christian ◽  
Davis C. Drinkwater ◽  
...  
2017 ◽  
Vol 6 (3) ◽  
pp. 5
Author(s):  
JuanCarlos Núñez-Enríquez ◽  
IsabelZnaya Ramírez-Flores ◽  
Maribel Ibarra-Sarlat ◽  
Vivian Neme-Bechara ◽  
Alejandro Herrera-Landero ◽  
...  

1993 ◽  
Vol 1 (3) ◽  
pp. 120-122
Author(s):  
Huang Huiming ◽  
Ding Wenxiang ◽  
Su Zhaokang ◽  
Cao Dinfang ◽  
Zhu Deming ◽  
...  

From April 1990 to December 1992, we used aprotinin in 80 pediatric cases undergoing cardiac surgery. Most patients had moderate to severe tetralogy of Fallot and other complex cyanotic diseases, and 12 cases were reoperated. One-half to one-third of the recommended dose was adopted, and 3 different patterns of administration were compared. All procedures achieved good results with less postoperative bleeding. We suggest the simplest procedure—adding 1 bolus dose of aprotinin to the pump prime—as the method of choice.


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Nils Dennhardt ◽  
Robert Sümpelmann ◽  
Alexander Horke ◽  
Oliver Keil ◽  
Katja Nickel ◽  
...  

Abstract Background Postoperative bleeding is a major problem in children undergoing complex pediatric cardiac surgery. The primary aim of this prospective observational study was to evaluate the effect of an institutional approach consisting of early preventive fibrinogen, prothrombin complex and platelets administration on coagulation parameters and postoperative bleeding in children. The secondary aim was to study the rate of re-intervention and postoperative transfusion, the occurrence of thrombosis, length of mechanical ventilation, ICU stay and mortality. Methods In fifty children (age 0–6 years) with one or more predefined risk factors for bleeding after cardiopulmonary bypass (CPB), thrombelastography (TEG) and standard coagulation parameters were measured at baseline (T1), after CPB and reversal of heparin (T2), at sternal closure (T3) and after 12 h in the ICU (T4). Clinical bleeding was evaluated by the surgeon at T2 and T3 using a numeric rating scale (NRS, 0–10). Results After CPB and early administration of fibrinogen, prothrombin complex and platelets, the clinical bleeding evaluation score decreased from a mean value of 6.2 ± 1.9 (NRS) at T2 to a mean value of 2.1 ± 0.8 at T3 (NRS; P <  0.001). Reaction time (R), kinetic time (K), maximum amplitude (MA) and maximum amplitude of fibrinogen (MA-fib) improved significantly (P <  0.001 for all), and MA-fib correlated significantly with the clinical bleeding evaluation (r = 0.70, P <  0.001). The administered total amount of fibrinogen (mg kg− 1) correlated significantly with weight (r = − 0.42, P = 0.002), priming volume as percentage of estimated blood volume (r = 0.30, P = 0.034), minimum CPB temperature (r = − 0.30, P = 0.033) and the change in clinical bleeding evaluation from T2 to T3 (r = 0.71, P <  0.001). The incidence of postoperative bleeding (> 10% of estimated blood volume) was 8%. No child required a surgical re-intervention, and no cases of thrombosis were observed. Hospital mortality was 0%. Conclusion In this observational study of children with an increased risk of bleeding after CPB, an early preventive therapy with fibrinogen, prothrombin complex and platelets guided by clinical bleeding evaluation and TEG reduced bleeding and improved TEG and standard coagulation parameters significantly, with no occurrence of thrombosis or need for re-operation. Trial registration German Clinical Trials Register DRKS00018109 (retrospectively registered 27th August 2019).


2020 ◽  
Vol 25 (6) ◽  
pp. 540-546
Author(s):  
Rachel B. Carroll ◽  
Hania Zaki ◽  
Courtney McCracken ◽  
Janet Figueroa ◽  
Nina A. Guzzetta

OBJECTIVES Postoperative bleeding is a common cause of morbidity and mortality in cardiac patients who undergo cardiopulmonary bypass (CPB). Pediatric patients are especially at risk for adverse effects of surgery and CPB on the coagulation system. This can result in bleeding, transfusions, and poor outcomes. Excessive bleeding unresponsive to blood products can warrant the off-label use of recombinant activated clotting factor VIIa (rFVIIa) and/or anti-inhibitor coagulant complex (FEIBA). Several studies have shown the utility in these agents off-label in patients who have undergone cardiac bypass surgery with acute bleeding episodes that are refractory to blood products. However, data regarding use of these agents in pediatrics are sparse. The purpose of this study is to report the use of rFVIIa and FEIBA in pediatric cardiac surgery patients in our institution. METHODS This was a retrospective chart review of pediatric cardiothoracic surgery patients who received rFVIIa or FEIBA at Children's Healthcare of Atlanta during the study period. RESULTS Thirty-three patients received rFVIIa and 9 patients received FEIBA either intraoperatively or postoperatively for bleeding related to the cardiac procedure. Approximately 13% of rFVIIa patients and 55% of FEIBA patients required repeat doses. There were decreases for all blood products administered after rFVIIa and FEIBA were given. However, the doses used did not correlate with either positive or negative outcomes. Seventeen percent (n = 7) of rFVIIa patients experienced a thrombus and 22% (n = 2) of FEIBA patients experienced a thrombus. CONCLUSIONS Both rFVIIa and FEIBA reduced blood product usage in pediatric patients following cardiac procedures.


2013 ◽  
Vol 61 (S 01) ◽  
Author(s):  
T Miyamoto ◽  
A Inui ◽  
T Yoshii ◽  
M Seki ◽  
K Nakajima ◽  
...  

2007 ◽  
Vol 55 (S 1) ◽  
Author(s):  
A Rastan ◽  
T Walther ◽  
A Fabricius ◽  
I Daehnert ◽  
J Hambsch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document